Clinical Trials Browser

Phase 3 × OTHER × aflutinib × Clear all

NCT06674343 2024-11-05

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung